Focus: Centaur Pharmaceuticals is an India-based generics and API manufacturer founded in 1996, specializing in small molecules with focus on neurology indications. The company operates in the competitive generic drug and contract manufacturing space.
Profile data last refreshed 10h ago · AI intelligence enriched 3w ago
No open roles listed right now. Follow Centaur Pharmaceuticals to get notified when they start hiring — the background below is worth knowing for when they do.
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Generic formulation of established anticonvulsant; post-LOE status indicates mature revenue phase with erosion risk.
Help build intelligence for Centaur Pharmaceuticals
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Generated by Claude from Centaur Pharmaceuticals's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
Duplicate post-LOE formulation; indicates portfolio concentration and limited innovation.
Pre-launch generic ANDA with SV2A mechanism; represents upcoming revenue opportunity but in crowded seizure market.
Additional post-LOE formulation; portfolio duplication limits diversification and growth.
Post-LOE formulation; mature asset with limited expansion potential.
Post-LOE formulation; recurring revenue erosion expected in commoditized seizure market.
Post-LOE formulation; narrow therapeutic focus limits commercial upside.
Post-LOE formulation; mature asset dependency increases revenue vulnerability.
Post-LOE formulation with SV2A mechanism detail; limited differentiation in generic space.
Post-LOE formulation; portfolio concentration on single molecule limits product diversification.
2 discontinued, 8 duplicate formulations not shown
No open positions listed yet. Check their careers page directly.
Source: USCIS H-1B Employer Data Hub
Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.
Upgrade to Pro — $25/mo